Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Calibrant and Yale University join hands in cancer research
Calibrant will identify proteins and protein networks involved in ovarian and breast cancer, as well as select novel therapeutic targets found to be central to disease progression. Fattaneh
Calibrant will identify proteins and protein networks involved in ovarian and breast cancer, as well as select novel therapeutic targets found to be central to disease progression. Fattaneh
The funding is part of the Maryland Technology Development’s Maryland Technology Transfer Fund (TEDCO MTTF) and the Maryland Venture Fund’s Challenge Investment Program. Using proprietary tissue processing technologies,
The application is based upon clinical data which include the results from the company’s Phase III multi-center, international, randomized study of Vidaza (azacitidine for injection) in the treatment
Under the research collaboration agreement, London Genetics’s partner, University College London (UCL), will replicate Genizon’s findings from the genome-wide association study that identified multiple genes associated with schizophrenia
New FDA-cleared indications for the Waterlase MD Derm device include incision, excision, ablation, vaporization and coagulation of dermatologic tissues including epidermal nevi, cheilitis, keloids, verrucae, skin tags, keratosis,
Under the terms of the agreement, Medicago will grant the partner two million common share purchase warrants. Each warrant entitles the partner the right to acquire one common
Additionally the company has reported that it has changed its name from Axela Biosensors to Axela, to reflect the broad range of applications and markets served by its
The committee reviewed data from a comprehensive clinical program comprising eight studies. Results from the clinical trials showed greater symptom improvement in Zyprexa long-acting injection (LAI) treated patients,
Under the terms of the agreement Novartis will fund additional research at Astex. Astex and Novartis originally entered into a research collaboration and licensing agreement in December 2005.
The patent relates to enteric coated formulations of crofelemer used to treat secretory diarrhea. The enteric coating allows crofelemer to pass through the stomach into the intestine where